1. Home
  2. SDGR vs XNCR Comparison

SDGR vs XNCR Comparison

Compare SDGR & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Schrodinger Inc.

SDGR

Schrodinger Inc.

HOLD

Current Price

$15.15

Market Cap

925.8M

Sector

Health Care

ML Signal

HOLD

Logo Xencor Inc.

XNCR

Xencor Inc.

HOLD

Current Price

$11.87

Market Cap

881.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDGR
XNCR
Founded
1990
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
925.8M
881.9M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
SDGR
XNCR
Price
$15.15
$11.87
Analyst Decision
Buy
Buy
Analyst Count
9
9
Target Price
$21.00
$22.33
AVG Volume (30 Days)
1.2M
648.0K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
45.14
65.36
EPS
N/A
N/A
Revenue
$255,869,000.00
$125,576,000.00
Revenue This Year
$0.76
N/A
Revenue Next Year
$4.60
$4.80
P/E Ratio
N/A
N/A
Revenue Growth
23.29
13.65
52 Week Low
$10.95
$6.92
52 Week High
$27.63
$18.69

Technical Indicators

Market Signals
Indicator
SDGR
XNCR
Relative Strength Index (RSI) 73.89 49.68
Support Level $11.27 $10.83
Resistance Level $19.51 $12.87
Average True Range (ATR) 0.71 0.58
MACD 0.22 0.02
Stochastic Oscillator 91.87 49.60

Price Performance

Historical Comparison
SDGR
XNCR

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Share on Social Networks: